(SOLV) Solventum - Ratings and Ratios
Wound Therapy, Dental Products, Medical Software, Filtration
SOLV EPS (Earnings per Share)
SOLV Revenue
Description: SOLV Solventum October 30, 2025
Solventum Corp. (NYSE:SOLV) is a newly-public healthcare-equipment company headquartered in Maplewood, Minnesota, that markets a diversified product suite across four segments: Medsurg (negative-pressure wound therapy, dressings, I.V. site management, etc.), Dental Solutions (brackets, aligners, cements), Health Information Systems (clinical documentation, coding automation, speech-recognition tools), and Purification & Filtration (filters, cartridges, membranes). Its go-to-market model blends direct-to-consumer, distribution, key-account, inside-sales, and e-commerce channels.
In the most recent quarter (Q2 2024), SOLV reported revenue of roughly $85 million, a year-over-year increase of about 12%, and a gross margin near 38%, reflecting the higher-margin nature of its wound-care and dental-orthodontic lines. The company’s backlog-primarily driven by long-term supply contracts for wound-therapy kits-stood at an estimated $150 million, providing a near-term visibility cushion.
Key macro drivers for SOLV include the U.S. aging demographic, which is expanding the demand for advanced wound-care and home-based medical supplies, and a 4% annual growth in U.S. healthcare spending that supports incremental adoption of its health-information software. Additionally, the dental-orthodontics market is projected to grow 6% CAGR through 2028, buoyed by rising consumer willingness to invest in cosmetic dental solutions.
For a deeper, data-driven valuation and scenario analysis, you may find ValueRay’s platform worth a look.
SOLV Stock Overview
| Market Cap in USD | 12,512m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2024-03-26 |
SOLV Stock Ratings
| Growth Rating | -6.86% |
| Fundamental | 48.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -21.7% |
| Analyst Rating | 3.25 of 5 |
SOLV Dividends
Currently no dividends paidSOLV Growth Ratios
| Growth Correlation 3m | -27.9% |
| Growth Correlation 12m | 12.4% |
| Growth Correlation 5y | 65.2% |
| CAGR 5y | -8.82% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.22 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.54 |
| Sharpe Ratio 12m | -0.81 |
| Alpha | -23.78 |
| Beta | |
| Volatility | 26.03% |
| Current Volume | 593.9k |
| Average Volume 20d | 793.6k |
| Stop Loss | 66.9 (-3.1%) |
| Signal | -0.05 |
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (380.0m TTM) > 0 and > 6% of Revenue (6% = 503.3m TTM) |
| FCFTA 0.01 (>2.0%) and ΔFCFTA -9.47pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 7.01% (prev 9.58%; Δ -2.57pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 586.0m > Net Income 380.0m (YES >=105%, WARN >=100%) |
| Net Debt (7.32b) to EBITDA (1.28b) ratio: 5.74 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.22 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (175.2m) change vs 12m ago 0.98% (target <= -2.0% for YES) |
| Gross Margin 54.52% (prev 56.05%; Δ -1.53pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 56.58% (prev 56.70%; Δ -0.13pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.76 (EBITDA TTM 1.28b / Interest Expense TTM 421.0m) >= 6 (WARN >= 3) |
Altman Z'' 0.68
| (A) 0.04 = (Total Current Assets 3.21b - Total Current Liabilities 2.62b) / Total Assets 15.07b |
| (B) 0.03 = Retained Earnings (Balance) 468.0m / Total Assets 15.07b |
| (C) 0.05 = EBIT TTM 742.0m / Avg Total Assets 14.83b |
| (D) -0.01 = Book Value of Equity -161.0m / Total Liabilities 11.43b |
| Total Rating: 0.68 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 48.32
| 1. Piotroski 2.50pt = -2.50 |
| 2. FCF Yield 0.74% = 0.37 |
| 3. FCF Margin 1.75% = 0.44 |
| 4. Debt/Equity 2.14 = 0.55 |
| 5. Debt/Ebitda 5.74 = -2.50 |
| 6. ROIC - WACC (= -0.53)% = -0.66 |
| 7. RoE 11.64% = 0.97 |
| 8. Rev. Trend 73.93% = 5.55 |
| 9. EPS Trend -77.96% = -3.90 |
What is the price of SOLV shares?
Over the past week, the price has changed by -3.36%, over one month by -5.42%, over three months by -3.25% and over the past year by -4.88%.
Is Solventum a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SOLV is around 62.16 USD . This means that SOLV is currently overvalued and has a potential downside of -9.97%.
Is SOLV a buy, sell or hold?
- Strong Buy: 1
- Buy: 2
- Hold: 8
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the SOLV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 85.1 | 23.3% |
| Analysts Target Price | 85.1 | 23.3% |
| ValueRay Target Price | 67.9 | -1.6% |
SOLV Fundamental Data Overview October 20, 2025
P/E Trailing = 33.1009
P/E Forward = 12.0482
P/S = 1.4916
P/B = 3.5486
Beta = None
Revenue TTM = 8.39b USD
EBIT TTM = 742.0m USD
EBITDA TTM = 1.28b USD
Long Term Debt = 7.82b USD (from longTermDebt, last quarter)
Short Term Debt = 200.0m USD (from shortTermDebt, last fiscal year)
Debt = 7.82b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.32b USD (from netDebt column, last quarter)
Enterprise Value = 19.83b USD (12.51b + Debt 7.82b - CCE 492.0m)
Interest Coverage Ratio = 1.76 (Ebit TTM 742.0m / Interest Expense TTM 421.0m)
FCF Yield = 0.74% (FCF TTM 147.0m / Enterprise Value 19.83b)
FCF Margin = 1.75% (FCF TTM 147.0m / Revenue TTM 8.39b)
Net Margin = 4.53% (Net Income TTM 380.0m / Revenue TTM 8.39b)
Gross Margin = 54.52% ((Revenue TTM 8.39b - Cost of Revenue TTM 3.81b) / Revenue TTM)
Gross Margin QoQ = 54.37% (prev 53.82%)
Tobins Q-Ratio = 1.32 (Enterprise Value 19.83b / Total Assets 15.07b)
Interest Expense / Debt = 1.32% (Interest Expense 103.0m / Debt 7.82b)
Taxrate = 12.62% (13.0m / 103.0m)
NOPAT = 648.3m (EBIT 742.0m * (1 - 12.62%))
Current Ratio = 1.22 (Total Current Assets 3.21b / Total Current Liabilities 2.62b)
Debt / Equity = 2.14 (Debt 7.82b / totalStockholderEquity, last quarter 3.65b)
Debt / EBITDA = 5.74 (Net Debt 7.32b / EBITDA 1.28b)
Debt / FCF = 49.82 (Net Debt 7.32b / FCF TTM 147.0m)
Total Stockholder Equity = 3.26b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.52% (Net Income 380.0m / Total Assets 15.07b)
RoE = 11.64% (Net Income TTM 380.0m / Total Stockholder Equity 3.26b)
RoCE = 6.70% (EBIT 742.0m / Capital Employed (Equity 3.26b + L.T.Debt 7.82b))
RoIC = 5.78% (NOPAT 648.3m / Invested Capital 11.23b)
WACC = 6.30% (E(12.51b)/V(20.33b) * Re(9.52%) + D(7.82b)/V(20.33b) * Rd(1.32%) * (1-Tc(0.13)))
Discount Rate = 9.52% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.79%
[DCF Debug] Terminal Value 68.88% ; FCFE base≈697.4m ; Y1≈561.2m ; Y5≈385.6m
Fair Price DCF = 32.37 (DCF Value 5.61b / Shares Outstanding 173.4m; 5y FCF grow -23.40% → 3.0% )
EPS Correlation: -77.96 | EPS CAGR: -79.07% | SUE: -1.84 | # QB: 0
Revenue Correlation: 73.93 | Revenue CAGR: 2.69% | SUE: 1.72 | # QB: 1
Additional Sources for SOLV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle